AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02861235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day
Description: with gamma-camera and D.SPECT camera, in Toulouse centre
Study NCT02861235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day
Description: with gamma-camera and D.SPECT camera, in Nancy centre
Study NCT02861235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days
Description: with gamma-camera and D.SPECT camera, in Paris centre
Study NCT02861235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera
Description: rest thallium-201 tomoscintigraphy for myocardial viability assessment
Study NCT02861235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera
Description: rest technetium-99m tomoscintigraphy for myocardial viability assessment
Study NCT04684017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: anlotinib 10 mg/day orally (from days 1 to 14 in a 21-day cycle)
Study NCT04684017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
Study NCT04684017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 iv on day 1 every 21 days for 4 cycles
Study NCT03776539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
Study NCT01368029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG ATCC 53103 (LGG)
Description: Study drug capsules (1x10\^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
Study NCT01368029 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
Study NCT05249738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring tongue cross-sectional area by submental ultrasonography
Description: The tongue cross-sectional areas of both groups were measured with submental ultrasonography to detect tongue edema.
Study NCT03014479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin
Description: Trelagliptin 100 mg or 50 mg
Study NCT03014479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily DPP-4 inhibitor
Description: Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
Study NCT02108964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: EGF816 will be dosed once daily. On the first day of each treatment cycle, the patient receives an adequate drug supply for self-administration at home. The investigator will instruct the patient to take EGF816 exactly as prescribed.
Study NCT02168491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
Study NCT00984932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg of rosuvastatin daily
Study NCT04758728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Great saphenous vein stripping and varicectomies
Description: Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
Study NCT04758728 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Great saphenous vein stripping and varicectomies
Description: Removal of the great saphenous vein (partially - from just below the knee up to the saphenofemoral junction) by two 3cm skin and subcutaneous fat incisions and the introduction of a conventional vein stripper device, under general or epidural/regional anesthesia. Removal of varicose veins of the lower limb by 0,5cm skin incisions and the use of a conventional phlebectomy stainless steel hook. Mechanical hemostasis by direct compression of the thigh for 10 minutes.
Study NCT04758728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Topical
Description: Use of epinephrine/adrenaline solution 1:1000 topically
Study NCT04758728 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: Use of normal saline solution NaCl 0,9% topically
Study NCT00844090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylphenidate or placebo
Description: treat apathy to improve diabetes self care behaviors thereby improving glycemic control
Study NCT00844090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate or placebo
Description: treat apathy to improve diabetes self care behaviors thereby improving glycemic control
Study NCT04486508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermediate dose Enoxaparin/ unfractionated heparin
Description: Intermediate dose anticoagulation according to creatinine clearance and weight
Study NCT04486508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard prophylactic dose Enoxaparin/ unfractionated heparin
Description: Standard prophylaxis anticoagulation according to creatinine clearance and weight
Study NCT04486508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: Statin
Study NCT04486508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo to atorvastatin 20 mg
Study NCT04249947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-PSMA-101 CAR-T cells
Description: P-PSMA-101 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target prostate cancer cells expressing the cell surface antigen prostate-specific membrane antigen (PSMA).
Study NCT04249947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated
Study NCT05385146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: qigong
Description: Chan-Chuang qigong with breathing meditation for 15 weeks
Study NCT02481076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowtron Hydroven and Coban2 Lite
Description: The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
Study NCT02481076 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Braun frame
Description: The leg is elevated on a Braun frame
Study NCT02481076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression bandage
Description: application of flowtron hydroven boot and compression bandage
Study NCT03747848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT group
Description: Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
Study NCT03507855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced noise
Description: All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
Study NCT03507855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal
Description: No change in the normal operating room environment.
Study NCT01536210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-162
Description: YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
Study NCT01536210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
Study NCT03796312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tub Bathing
Description: The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
Study NCT03796312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sponge Bathing
Description: Sponge bathing is routine care of the clinic
Study NCT02365935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A adjuvant chemotherapy
Description: In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
Study NCT02365935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B adjuvant chemotherapy
Description: In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
Study NCT02365935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02365935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02048722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Given PO
Study NCT00514618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
Study NCT00514618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
Study NCT03924323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 8-weeks of treatment followed by 1-week taper down period
Study NCT03924323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral administration of inactive substance once daily
Study NCT01064271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone Tablets 1 mg
Study NCT01064271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone Tablets 1 mg
Study NCT01545388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
Study NCT01545388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
Study NCT01545388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
Study NCT01545388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
Study NCT01545388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks
Study NCT01545388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks
Study NCT02567188 — intervention group
Intervention type: OTHER
Intervention: MIRCERA
Study NCT02136537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral NMES legs
Description: Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
Study NCT02136537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical therapy
Description: Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
Study NCT02136537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical therapy
Description: Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
Study NCT00432900 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [(11)C]PBR28
Description: PET Ligand
Study NCT00432900 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [(11)C]PBR28
Description: PET Ligand
Study NCT02247466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium and Sugammadex
Study NCT01825200 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok
Description: A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
Study NCT01825200 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Afluria
Description: Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
Study NCT02570386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh embryo transfer
Description: Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
Study NCT02570386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frozen embryo transfer
Description: Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
Study NCT04192240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB Training with external feedback
Description: WB during sit-to-stand and stepping with external feedback, follow by overground walking.
Study NCT04192240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WB Training without external feedback
Description: WB during sit-to-stand and stepping without external feedback, follow by overground walking.
Study NCT01161810 — intervention group
Intervention type: OTHER
Intervention: Routine post burn rehabilitation therapy
Description: No testing outside of routine clinical rehabilitation will be performed
Study NCT02718911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3022855
Description: Administered IV
Study NCT02718911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered IV
Study NCT02718911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Administered IV
Study NCT01132183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study NCT01132183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study NCT02728063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactibiane Tolerance
Description: probiotics
Study NCT03781466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage indicated by short cervix ≤25mm
Study NCT03781466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone
Description: Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
Study NCT02604030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb function
Description: Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
Study NCT01909804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT01909804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEL
Description: Tablet administered orally once daily
Study NCT01909804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT05854420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified anterior Lamellar Recession
Description: ALR is one of the procedures used to treat cicatricial entropion and trichiasis. Few studies present the effect of modifications to this procedure in trachomatous entropion and trichiasis. Because trachoma is common in our country, there is a probability that the number of surgeries for TT will rise.
Study NCT03565757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART intervention
Description: All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
Study NCT00889941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Description: laser-assisted in situ keratomileusis
Study NCT04168528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68GaNOTA-Anti-MMR-VHH2
Description: Injection of the radiopharmaceutical and PET/CT imaging
Study NCT03894709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-centered care model
Description: Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
Study NCT03589807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
Study NCT02368457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and Tocopherol
Description: pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
Study NCT03890003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID system